[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU3236793A - Recombinant and chimeric antibodies to c-erbB-2 - Google Patents

Recombinant and chimeric antibodies to c-erbB-2

Info

Publication number
AU3236793A
AU3236793A AU32367/93A AU3236793A AU3236793A AU 3236793 A AU3236793 A AU 3236793A AU 32367/93 A AU32367/93 A AU 32367/93A AU 3236793 A AU3236793 A AU 3236793A AU 3236793 A AU3236793 A AU 3236793A
Authority
AU
Australia
Prior art keywords
erbb
recombinant
chimeric antibodies
chimeric
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32367/93A
Inventor
John W Brandis
Hsiao-Lai C Liu
Michael P McBrogan
Deborah L Parkes
Laura K Shawver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlex Laboratories Inc
Original Assignee
Berlex Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlex Laboratories Inc filed Critical Berlex Laboratories Inc
Publication of AU3236793A publication Critical patent/AU3236793A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU32367/93A 1991-12-12 1992-12-04 Recombinant and chimeric antibodies to c-erbB-2 Abandoned AU3236793A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US808462 1985-12-13
US80846291A 1991-12-12 1991-12-12

Publications (1)

Publication Number Publication Date
AU3236793A true AU3236793A (en) 1993-07-19

Family

ID=25198826

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32367/93A Abandoned AU3236793A (en) 1991-12-12 1992-12-04 Recombinant and chimeric antibodies to c-erbB-2

Country Status (2)

Country Link
AU (1) AU3236793A (en)
WO (1) WO1993012220A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006217A1 (en) * 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
WO1994005332A2 (en) * 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CA2382100A1 (en) 1999-08-27 2001-03-08 Genentech, Inc. Dosages for treatment with anti-erbb2 antibodies
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
DK1819358T3 (en) 2004-11-18 2014-10-27 Imclone Llc Antibodies to Vascular Endothelial Growth Factor Receptor-1
KR20190016616A (en) 2005-01-21 2019-02-18 제넨테크, 인크. Fixed dosing of her antibodies
PL1850874T3 (en) 2005-02-23 2014-03-31 Genentech Inc Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
RU2504553C2 (en) 2009-03-20 2014-01-20 Дженентек, Инк. Antibodies to her
CN102421448A (en) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Modulators for her2 signaling in her2 expressing patients with gastric cancer
DK2536748T3 (en) 2010-02-18 2014-10-13 Genentech Inc NEUREGULIN ANTAGONISTS AND ITS USE IN TREATMENT OF CANCER
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
MX2014001766A (en) 2011-08-17 2014-05-01 Genentech Inc Neuregulin antibodies and uses thereof.
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
CN104271761B (en) 2011-11-30 2017-03-15 霍夫曼-拉罗奇有限公司 Erbb3 mutation in cancer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
BR112014024017A8 (en) 2012-03-27 2017-07-25 Genentech Inc METHODS FOR TREATMENT OF A TYPE OF CANCER, FOR TREATMENT OF CARCINOMA, FOR SELECTING A THERAPY AND FOR QUANTIFICATION AND HER3 INHIBITORS
EP2926142B2 (en) 2012-11-30 2022-07-06 F. Hoffmann-La Roche AG Identification of patients in need of pd-l1 inhibitor cotherapy
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies

Also Published As

Publication number Publication date
WO1993012220A1 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
AU3236793A (en) Recombinant and chimeric antibodies to c-erbB-2
AU4025193A (en) Humanized C-erbB-2 specific antibodies
AU625613B2 (en) Novel chimeric antibodies
AU645187B2 (en) Freeze-dried preparation containing monoclonal antibody
AU5283893A (en) Recombinant humanized anti-cytomegalovirus antibodies
SG48420A1 (en) Humanized antibodies and uses thereof
AU5283793A (en) Recombinant specific binding protein
AU4382193A (en) BPI-immunoglobulin fusion proteins
AU3342689A (en) Luminescent chimeric proteins
GB8800077D0 (en) Novel chimeric antibodies
AU4618193A (en) Humanized antibodies
IL100764A0 (en) Monoclonal antibodies to elam-1 and their uses
GB9415380D0 (en) Recombinant antibodies specific for tnf-
AU635996B2 (en) Recombinant human anti-cd18 antibodies
AU3459593A (en) Humanised antibody against hepatitis
GB9412166D0 (en) Retargetting antibodies
AU3665293A (en) Chimeric toxins binding to the GnRH receptor
AU4271793A (en) Novel polypeptide
AU1025692A (en) Novel chimeric antiidiotypic monoclonal antibodies
AU5647894A (en) Chimeric human interferon-gamma-receptor/immunoglobulin polypeptides
AU7796291A (en) High affinity antibodies to small peptides
AU4889393A (en) Human monoclonal anti-peptide antibody and DNA encoding thereof
AU6059194A (en) Monoclonal antibodies to bovine cytokines
GB9220808D0 (en) Antibody genes
EP0491351A3 (en) Chimeric antibodies and their use